ASC30 vs ecnoglutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

ASC30

Developed by Ascletis Pharma

Phase 3 in Obesitysmall molecule
Partial signal

NCT07002905 · Phase 2 · completed

The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: July 2028 · NCT07743463 (registry estimate)

Reported efficacy

Percent change in body weight from Baseline up to Week 13 (Baseline and Week 13): Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo (met)

Result source: NCT07002905

ecnoglutide

Marketed by Pfizer under a licence from Sciwind Biosciences

Phase 3 in Obesitypeptide
Reliable signal

NCT05813795 · Phase 3 · completed

SLIMMER was a randomized, double-blind, placebo-controlled Phase 3 trial at 36 centres in China. It assigned 664 adults with overweight or obesity and without diabetes to once-weekly ecnoglutide 1.2 mg, 1.8 mg or 2.4 mg or placebo. The two primary endpoints at week 40 were the percent change in body weight and the proportion of participants who lost at least 5% of their body weight. All three doses were significantly better than placebo on both endpoints (all p<0.0001), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in The Lancet Diabetes and Endocrinology.

Next expected readout: February 2027 · NCT07073417 (registry estimate)

Reported efficacy

Co-primary: percent change in body weight from baseline to week 40, and proportion of participants with at least 5% body-weight reduction at week 40: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met. (met)

Result source: NCT05813795

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointASC30ecnoglutide
Body weight, % change—Trial running · NCT07743463-13.2% vs 0.1%a−13.3 vs placeboecnoglutide 2.4 mg · wk 40NCT05813795
Weight loss of 5% or more—Trial running · NCT07743463—Not posted · NCT05813795
Weight loss of 10% or more—Trial running · NCT07743463—Not posted · NCT05813795
Waist circumference, change (cm)—Trial running · NCT07743463—Not posted · NCT05813795

Body weight, % change

ASC30
—Trial running · NCT07743463
ecnoglutide
-13.2% vs 0.1%a−13.3 vs placeboecnoglutide 2.4 mg · wk 40NCT05813795

Weight loss of 5% or more

ASC30
—Trial running · NCT07743463
ecnoglutide
—Not posted · NCT05813795

Weight loss of 10% or more

ASC30
—Trial running · NCT07743463
ecnoglutide
—Not posted · NCT05813795

Waist circumference, change (cm)

ASC30
—Trial running · NCT07743463
ecnoglutide
—Not posted · NCT05813795
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ASC30

Weight 7.7% @ 13wk60mg ASC30
percent change · % of baseline
No placebo or comparator arm
NCT07002905 · Phase 2 · sponsor-reported, not registry data
show 2 more results
7% @ 13wk40mg ASC30
NCT07002905 · Phase 2 · sponsor-reported, not registry data
5.4% @ 13wk20mg ASC30
NCT07002905 · Phase 2 · sponsor-reported, not registry data

ecnoglutide

Weight -13.2% vs 0.1% placebo @ 40wkecnoglutide 2.4 mg
percent change · % of baseline
NCT05813795 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · ecnoglutide's landscape